Recludix Pharma Participation in Investor Conferences
Recludix Pharma, renowned for its innovative work in developing inhibitors for complex inflammatory diseases, is gearing up for an exciting December. Members of its management team will actively participate in two significant investor conferences designed to engage stakeholders and showcase the company's pioneering research efforts.
Citi 2024 Global Healthcare Conference
The first conference on Recludix Pharma's agenda is the Citi 2024 Global Healthcare Conference, set to take place in Miami. This event offers a valuable platform for networking and discussions. The management team will be available for meetings on December 3, providing an opportunity for potential investors and partners to gain insights into the company's progress and future goals.
Evercore HealthCONx Conference Engagement
Following the Citi event, Recludix Pharma will participate in the Evercore HealthCONx Conference on December 4. This conference promises an engaging fireside chat scheduled from 3:25 to 3:45 p.m. ET. Attendees can anticipate a detailed discussion about Recludix’s strategies and targets, particularly its advancements in drug development for inflammatory diseases.
Webcast Opportunities
For those unable to attend in person, the Evercore HealthCONx Conference will feature both live and archived webcasts. Interested parties can access these sessions to ensure they stay updated on Recludix Pharma's latest developments and strategic outlook.
About Recludix Pharma
Recludix continues to stand out in the biotech arena with its unique platform for developing selective inhibitors targeting complex protein structures. The company is led by seasoned professionals from prestigious organizations such as Seagen, Blueprint Medicines, and Lilly. Their innovative drug discovery platform combines custom-generated DNA-encoded libraries with advanced screening methods to enhance selectivity and efficacy in the development of their therapeutic solutions.
Focus on STAT Proteins
Currently, Recludix Pharma's most advanced programs concentrate on STAT (signal transducer and activator of transcription) proteins. These proteins are intricately linked with inflammatory diseases, including rheumatoid arthritis and asthma. By targeting the abnormal activation of STAT proteins, the company aims to bring forth effective treatments that address the root causes of these debilitating conditions.
Strategic Partnerships and Innovations
Recludix Pharma is strategically partnered with major industry player Sanofi for the development and commercialization of a STAT6 inhibitor. Additionally, the company is making strides with its STAT3 inhibitors, further expanding its portfolio aimed at treating Th17-mediated inflammatory and immune diseases.
Acknowledgment in the Biotech Community
In recognition of its innovative contributions to the biotech field, Recludix has been named one of the 2024 Fierce 15 biotech companies. This accolade emphasizes the company's dedication to advancing healthcare through cutting-edge research and development.
Contact Information for Recludix
For more information regarding their research, upcoming events, or inquiries, interested parties can reach out to Recludix through the following contacts:
Matt Caldemeyer
Chief Business Officer
mcaldemeyer@recludix.com
Alexandra Santos
asantos@wheelhouselsa.com
Aljanae Reynolds
areynolds@wheelhouselsa.com
Frequently Asked Questions
What conferences is Recludix Pharma participating in December?
Recludix Pharma will participate in the Citi 2024 Global Healthcare Conference and the Evercore HealthCONx Conference in December.
Where will the Citi Conference take place?
The Citi Conference will be held in Miami, Florida.
What is the focus of Recludix Pharma's drug development?
Recludix focuses on developing inhibitors for STAT proteins linked to inflammatory diseases.
Who are Recludix's strategic partners?
Recludix Pharma has a strategic partnership with Sanofi for the development of a STAT6 inhibitor.
How can one contact Recludix Pharma for inquiries?
Inquiries can be directed to Matt Caldemeyer via email at mcaldemeyer@recludix.com, or to Alexandra Santos and Aljanae Reynolds through their respective email addresses.
